Michael E. Karellas, MD, FACS
Assistant Professor of UrologyCards
About
Research
Publications
2014
Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy
Sfakianos J, Hakimi A, Kim P, Zabor E, Mano R, Bernstein M, Karellas M, Russo P. Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. European Journal Of Surgical Oncology 2014, 40: 1700-1705. PMID: 24813810, PMCID: PMC4208948, DOI: 10.1016/j.ejso.2014.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAnticoagulantsAspirinBlood TransfusionFemaleFibrinolytic AgentsHumansIncidenceIntraoperative ComplicationsKidney NeoplasmsLength of StayMaleMiddle AgedNeoplasm StagingNephrectomyPlatelet Aggregation InhibitorsPostoperative ComplicationsRetrospective StudiesRisk FactorsSeverity of Illness IndexTreatment OutcomeUnited StatesConceptsOverall complication rateComplication rateChronic anticoagulationRenal tumorsChronic anticoagulation therapyLength of stayLogistic regression modelsACT patientsAspirin patientsChronic aspirinHigher transfusionAnticoagulation therapyASA scoreAspirin useTransfusion rateAnticoagulation groupSurgical resectionMedian lengthOpen surgeryClinical differencesRenal surgeryGrade 3Renal cancerRetrospective analysisAnticoagulationMP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES
Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES. Journal Of Urology 2014, 191: e927. DOI: 10.1016/j.juro.2014.02.2500.Peer-Reviewed Original ResearchRenal Calculi
Conn’s Current Therapy, 2014 Edition, Ed. Bope, et al., Philadelphia: Saunders.Chapters
2013
1645 ROBOT ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY VERSUS OPEN PARTIAL NEPHRECTOMY: UTILIZATION AND COST ANALYSIS
Parihar J, Su D, Dombrovskiy V, Jang T, Karellas M. 1645 ROBOT ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY VERSUS OPEN PARTIAL NEPHRECTOMY: UTILIZATION AND COST ANALYSIS. Journal Of Urology 2013, 189: e676. DOI: 10.1016/j.juro.2013.02.3111.Peer-Reviewed Original ResearchIncreased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance
Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkAA menRadical prostatectomyActive surveillanceProstate cancerNCCN criteriaBiopsy coresAS criteriaAS inclusion criteriaFinal surgical pathologyComprehensive Cancer NetworkPositive biopsy coresDatabase of menWorse clinicopathological featuresAfrican American menPathological upstagingAdvanced diseaseIndependent predictorsPathologic characteristicsClinicopathological featuresPreoperative PSAClinicopathologic findingsWA patientsInclusion criteriaPositive cores
2012
Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy
Teloken P, Nelson C, Karellas M, Stasi J, Eastham J, Scardino P, Mulhall J. Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy. BJU International 2012, 111: 653-657. PMID: 22758405, DOI: 10.1111/j.1464-410x.2012.11321.x.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAnalysis of VarianceAustraliaDatabases, FactualDiabetes MellitusErectile DysfunctionFollow-Up StudiesHumansHypercholesterolemiaHypertensionMaleMiddle AgedMultivariate AnalysisPenile ErectionProspective StudiesProstatectomyProstatic NeoplasmsRecovery of FunctionRegression AnalysisRisk FactorsSmokingTreatment OutcomeVascular DiseasesConceptsVascular risk factorsErectile function recoveryPreoperative erectile functionRadical prostatectomyFunction recoveryErectile functionRisk factorsPatient factorsSurgical techniquePresence of VRFNerve-sparing statusPostoperative erectile functionNew treatment strategiesProspective databaseEF recoverySTUDY ADDDiabetes mellitusMultivariable analysisCigarette smokingErectile dysfunctionPatient counsellingUnivariate analysisProstate cancerTreatment strategiesPreoperative information
2011
Management of Non-Germ Cell Testis Tumors
Karellas ME and Holzbeierlein JM, “Management of Non-Germ Cell Testis Tumors.” in Comprehensive Textbook of Genitourinary Oncology, 4th Edition. Ed. Vogelzang, et al. Philadelphia:Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011. 629-634.Chapters
2010
Partial nephrectomy for selected renal cortical tumours of ≥7 cm
Karellas M, O’Brien M, Jang T, Bernstein M, Russo P. Partial nephrectomy for selected renal cortical tumours of ≥7 cm. BJU International 2010, 106: 1484-1487. PMID: 20518765, PMCID: PMC4319322, DOI: 10.1111/j.1464-410x.2010.09405.x.Peer-Reviewed Original ResearchConceptsRenal cortical tumorsPartial nephrectomyCortical tumorsRenal unitsLarge tumorsPre-existing renal insufficiencyUse of PNConventional clear cell carcinomaAccepted surgical approachMedian tumor sizeGlomerular filtration rateInstitutional review board approvalClear cell carcinomaEffective tumor controlReview board approvalRenal insufficiencySolitary kidneyMetastatic diseaseMedian ageAppropriate tumorSurgical databaseTumor sizeCell carcinomaSurgical approachTumor control1654 LONG TERM SURVIVAL RATES AFTER RESECTION FOR LOCALLY ADVANCED KIDNEY CANCER
O'Brien M, Jang T, Cronin A, von Bodman C, Lowrance W, Bernstein M, Karellas M, Russo P. 1654 LONG TERM SURVIVAL RATES AFTER RESECTION FOR LOCALLY ADVANCED KIDNEY CANCER. Journal Of Urology 2010, 183: e639. DOI: 10.1016/j.juro.2010.02.1457.Peer-Reviewed Original ResearchEditorial Comment
Karellas M. Editorial Comment. Journal Of Urology 2010, 183: 137. PMID: 19913247, DOI: 10.1016/j.juro.2009.08.198.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Michael Karellas, MD, is a urologic oncologist who treats urologic cancers, including bladder, kidney, prostate, and testicular cancer. He also treats general urology conditions such as kidney stones.
Dr. Karellas originally wanted to be a pharmacist but became interested in caring for patients in college. Then, in medical school, he found himself drawn to surgery. “In urology, I like that the nature of our surgery is generally curative,” he says.
Dr. Karellas recognizes the importance of working with patients to determine the best course of treatment for them. Most cancers have clinical guidelines based on standardized data to help determine which scientifically proven approach might best treat their cancer, he explains. “However, guidelines are not mandates, and I always discuss options with patients,” he says. “I listen to the patient to learn about their wishes, wants, and treatment goals. Then, I merge those with the standardized treatments to offer the best care possible for them.”
In addition to his clinical practice, Dr. Karellas is the director of the Western Division of Urology for Yale Medicine, an assistant professor of urology for Yale School of Medicine, and a researcher interested in a variety of urological treatments.
Clinical Specialties
Urology; Urologic Oncology; Minimally Invasive Surgery; Stone Disease
Board Certifications
Urology
- Certification Organization
- AB of Urology
- Latest Certification Date
- 2022
- Original Certification Date
- 2012
News
News
- February 21, 2025Source: WTNH News 8 (with Dr. Michael Karellas)
Hair Dye Exposure and Bladder Cancer
- July 30, 2024
Yale Urology Welcomes New Faculty
- March 27, 2024
New Leadership and Long-term Plans at Yale Urology West
- January 12, 2024Source: Urology Times
AI and urologic oncology: An expert’s view
Get In Touch
Contacts
Office Fax Number
Appointment Number
Mailing Address
Urology
333 Cedar Street, P.O. Box 208058
New Haven, CT 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.